Abstract

BackgroundOpioid use disorder (OUD) is a major risk factor in the acquisition and transmission of HIV. Clinical practice guidelines call for the integration of HIV services in OUD treatment. This mixed methods study describes the integration of HIV services in buprenorphine treatment and examines whether HIV services vary by prescribers’ medical specialty and across practice settings.MethodsData were obtained via qualitative interviews with buprenorphine experts (n = 21) and mailed surveys from US buprenorphine prescribers (n = 1174). Survey measures asked about screening for HIV risk behaviors at intake, offering HIV education, recommending all new patients receive HIV testing, and availability of on-site HIV testing. Prescribers’ medical specialty, practice settings, caseload demographics, and physician demographics were measured. Multivariate models of HIV services were estimated, while accounting for the nesting of physicians within states.ResultsQualitative interviews revealed that physicians often use injection behaviors as the primary indicator for whether a patient should be tested for HIV. Interviews revealed that HIV-related services were often viewed as beyond the scope of practice among general psychiatrists. Surveys indicated that prescribers screened for an average of 3.2 of 5 HIV risk behaviors (SD = 1.6) at intake. About 62.0% of prescribers delivered HIV education to patients and 53.2% recommended HIV testing to all new patients, but only 32.3% offered on-site HIV testing. Addiction specialists and psychiatrists screened for significantly more HIV risk behaviors than physicians in other specialties. Addiction specialists and psychiatrists were significantly less likely than other physicians to offer on-site testing. Physicians in individual medical practice were significantly less likely to recommend HIV testing and to offer onsite testing than physicians in other settings.ConclusionsBuprenorphine treatment providers have not uniformly integrated HIV-related screening, education, and testing services for patients. Differences by medical specialty and practice setting suggest an opportunity for targeting efforts to increase implementation.

Highlights

  • Opioid use disorder (OUD) is a major risk factor in the acquisition and transmission of HIV

  • Despite the strong links between OUD and HIV/AIDS, services for these two conditions have been fragmented in the United States, with HIV clinical care occurring in medical settings and OUD services located in clinics that are not

  • HIV testing is included among the preventive services that are covered under the Affordable Care Act [18]

Read more

Summary

Introduction

Opioid use disorder (OUD) is a major risk factor in the acquisition and transmission of HIV due to injection and high-risk sexual behaviors [1, 2]. Despite the strong links between OUD and HIV/AIDS, services for these two conditions have been fragmented in the United States, with HIV clinical care occurring in medical settings and OUD services located in clinics that are not. Such integration may yield numerous health-related benefits. While buprenorphine treatment itself is an important HIV prevention strategy, HIV testing and brief interventions to decrease risky sexual behaviors represent additional services that may yield public health benefits [2]. Subsequent linkage to ART for individuals with HIV, and ART adherence have benefits for the health of individuals, and by reducing the individual’s viral load, prevents the further spread of HIV [19]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call